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Available online 3 July 2017Aims: Ischaemic cardiovascular disease is amajor cause ofmorbidity andmortalityworldwide. Despite promising
results from pre-clinical animal models, VEGF-based strategies for therapeutic angiogenesis have yet to achieve
successful reperfusion of ischaemic tissues in patients. Failure to restore efﬁcient VEGF activity in the ischaemic
organ remains a major problem in current pro-angiogenic therapeutic approaches. Plasma membrane calcium
ATPase 4 (PMCA4) negatively regulates VEGF-activated angiogenesis via inhibition of the calcineurin/NFAT sig-
nalling pathway. PMCA4 activity is inhibited by the small molecule aurintricarboxylic acid (ATA). We hypothe-
size that inhibition of PMCA4 with ATA might enhance VEGF-induced angiogenesis.
Methods and results:We show that inhibition of PMCA4 with ATA in endothelial cells triggers a marked increase
in VEGF-activated calcineurin/NFAT signalling that translates into a strong increase in endothelial cell motility
and blood vessel formation. ATA enhances VEGF-induced calcineurin signalling by disrupting the interaction be-
tween PMCA4 and calcineurin at the endothelial-cell membrane. ATA concentrations at the nanomolar range,
that efﬁciently inhibit PMCA4, had no deleterious effect on endothelial-cell viability or zebraﬁsh embryonic de-
velopment. However, high ATA concentrations at themicromolar level impaired endothelial cell viability and tu-
bular morphogenesis, and were associated with toxicity in zebraﬁsh embryos. In mice undergoing
experimentally-induced hindlimb ischaemia, ATA treatment signiﬁcantly increased the reperfusion of post-isch-
aemic limbs.
Conclusions: Our study provides evidence for the therapeutic potential of targeting PMCA4 to improve VEGF-
based pro-angiogenic interventions. This goal will require the development of reﬁned, highly selective versions
of ATA, or the identiﬁcation of novel PMCA4 inhibitors.
© 2017 Elsevier Ltd. All rights reserved.Keywords:
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Ischaemic cardiovascular diseases (including ischaemic heart dis-
ease, peripheral arterial disease, and stroke) constitute a leading cause
of morbidity and mortality worldwide [28]. In some patients, bypass
surgery and interventional endovascular procedures can successfully
restore blood ﬂow to the ischaemic tissue [1,33]. However, the
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vascularization in a high proportion of patients [1]. Therapeutic strate-
gies to promote the formation of new blood vessels in the ischaemic
organ (referred to as therapeutic angiogenesis) constitute a promising
alternative for these patients [1,11,42].
Angiogenesis, the formation of new blood vessels from pre-
existing ones, is a tightly regulated process involving the participa-
tion of several pro- and anti-angiogenic factors [10]. One of the crit-
ical pro-angiogenic factors is vascular endothelial growth factor
(VEGF) [38]. A number of gene-based and protein-based approaches
have been developed to deliver exogenous VEGF to ischaemic tissues
[42]. Data obtained in animal models of myocardial and limb ischae-
mic disease demonstrated that VEGF-based pro-angiogenic thera-
pies induce successful reperfusion of the ischaemic organ [40].
Unfortunately, to date clinical translation of these procedures has
produced only limited patient beneﬁt [12]. The reasons for the lack
of clinical success with therapeutic angiogenesis approaches are
complex, but one central problem in current approaches is failure
to restore efﬁcient VEGF activity in the ischaemic organ [12,40,42].
Design of new, more effective treatments requires a deep under-
standing of the molecular and biochemical processes governing
VEGF-induced angiogenesis.
We recently reported a novel role for plasma membrane calcium
ATPase 4 (PMCA4) as a negative regulator of VEGF-activated angio-
genesis [4]. PMCAs are enzymatic high-afﬁnity systems that export
calcium from the cytosol to the extracellular environment [37].
There are four PMCA isoforms (PMCA1–4) encoded by four distinct
genes [37]. PMCA1 and 4 are expressed ubiquitously, whereas
PMCA2 and 3 are restricted to highly specialised cells and tissues
[37]. PMCA4 is the major isoform present in endothelial cells [30].
Our previous work showed that PMCA4 attenuates VEGF-induced
angiogenesis by establishing an inhibitory interaction with the
signalling protein calcineurin [4]. Calcineurin is a serine/threonine
phosphatase activated by increases in cytosolic calcium concentra-
tion [20]. Activated calcineurin mediates dephosphorylation of
NFAT (nuclear factor of activated T cells) transcription factors,
promoting their translocation to the nucleus and the subsequent
expression of NFAT-target genes [15]. The calcineurin/NFAT signal-
ling axis plays a critical role in VEGF-induced angiogenesis [2,14].
PMCA4 is thought to downregulate calcineurin activity by tethering
it to low-calcium micro-domains created by the pump's calcium
expulsion action and, in so doing, impair VEGF-activated pro-angio-
genic signalling [4]. We therefore hypothesize that pharmacological
blockade of PMCA4 function, and thus suppression of the negative
effect of PMCA4 on angiogenesis, might potentiate the efﬁciency
of therapeutic strategies involving VEGF. Supporting this possibility,
we previously reported more efﬁcient limb reperfusion in PMCA4−/−
knockout mice undergoing femoral artery ligation than in their wild-
type littermates [4].
A recent study showed that low concentrations of the small
molecule aurintricarboxylic acid (ATA) strongly inhibit the calcium
extrusion activity of PMCA4 without affecting the activity of
PMCA1 or other major calcium pumps such as SERCA and
the Na+/K+ ATPase [26]. This ﬁnding prompted us to examine
whether inhibition of PMCA4 with ATA enhances VEGF-induced
angiogenesis.
Here, we show that treatment of primary endothelial cells with
low concentrations of ATA results in a remarkable increase in
VEGF-mediated activation of the calcineurin/NFAT pathway
and in the expression of the VEGF-induced, NFAT-dependent,
pro-angiogenic protein RCAN1.4. Inhibition of PMCA4 with ATA
also enhances endothelial cell motility and tubular morphogenesis,
with no harmful effects on the cells. These results highlight the
clinical potential of targeting PMCA4 to improve VEGF-based
therapeutic interventions that promote blood vessel formation
in patients suffering from ischaemic cardiovascular disease.2. Materials and methods
2.1. Cells and cell culture
Human umbilical vein endothelial cells (HUVEC) were purchased
from TCS Cellworks and cultured in tissue culture ﬂasks pre-coated
with 0.1% gelatin in endothelial cell growth medium (ECGM,
PromoCell) supplemented with ECGM-supplement mix and 1% penicil-
lin/streptomycin/amphotericin B (Sigma-Aldrich). HUVECs were used
at passages 6–8.
Mouse lung endothelial cells (MLEC) were puriﬁed from wild-type
or PMCA4-null mice as described [4]. Generation and characterization
of PMCA4 knockout mice has been previously reported [34].
2.2. Luciferase reporter assay
HUVECs were infected with Ad-NFAT-Luc (a replication-deﬁcient
adenovirus harbouring an NFAT-dependent, luciferase-based reporter
system) at a multiplicity of infection (MOI) of 50. Generation of Ad-
NFAT-Luc-infected particles was as described [4]. Infected cells were
incubated in ECGM containing 0.5% fetal calf serum for 16 h and then
stimulated with VEGF (25 ng/ml) for 6 h. Luciferase activity was
determined as described [17].
2.3. siRNA gene knock-down
siRNA-mediated knock-down of PMCA4 gene expression was
performed using “ON-TARGET-plus SMART pool human ATP2B4”
(Thermo Scientiﬁc). “ON-TARGET-plus non-targeting pool control
duplexes” (Thermo Scientiﬁc) was used as a control.
For siRNA transfection, HUVECswere plated in 0.1% gelatin pre-coat-
ed 6-well tissue culture plates (3 × 105 cells/well) and incubated over-
night. The following morning, cells were washed with PBS and
incubated in serum-free, antibiotic-free OPTIMEM medium for 1 h.
Then, 100 pmol of siRNA/well were transfected using 5 μl of Lipofecta-
mine 2000 (Thermo Scientiﬁc). Transfection medium was removed
after incubation for 6 h, and substituted by ECGM supplemented with
ECGM-supplement mix and 1% penicillin/streptomycin/amphotericin
B (Sigma-Aldrich). Cells were incubated for 72 h and then used for
further experiments.
2.4. Quantitative Real-Time PCR
Total RNA fromHUVECswas extractedusing the “Total RNApuriﬁca-
tion kit” (Norgen) and cDNA synthesis was performed with 0.5 μg of
total RNA using the “High capacity cDNA reverse transcription kit” (Ap-
plied Biosystems). PMCA4 RNA expression was determined by qRT-PCR
using TaqMan Gene Expression Assay (Hs00608066_m1) in a 7500 Fast
Real-TimePCRSystem (Applied Biosystems, UK). PCR cycling conditions
consisted of an initial enzyme activation step at 95 °C for 10min, follow-
ed by denaturation at 95 °C for 15 s, and annealing and extension at 60
°C for 1 min for 40 cycles. Ct value was normalised using the Ct values
for the housekeeping gene Hprt-1 (TaqMan Gene Expression Assay,
Hs99999909_m1). Analysis of data was carried out using the compara-
tive 2−ΔΔCT method.
2.5. Western blot
Total proteins were isolated by direct lysis of HUVECs, treated as
indicated, in NuPAGE LDS sample buffer containing 0.05% β-
mercaptoethanol. Membrane-associated proteins were isolated using
the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem) as
reported [3].
We have noticed that repeated and prolonged boiling degrades en-
dothelial PMCA4; therefore we minimised repeated cycles of freeze-
thawing-boiling. Protein samples were boiled for 1 min and then
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are described in detail in the online Supplementary material.
2.6. Immunoprecipitation
HUVECs were stimulated for 4 h with VEGF (25 ng/ml) in the
presence of ATA (250 nM) or vehicle (DMSO), and PMCA4/calcineurin
complexes were immunoprecipitated from 4 mg total protein extract
with anti-calcineurin A monoclonal antibody (Sigma) using the Pierce
Co-Immunoprecipitation Kit. To immunoprecipitate the PMCA4/eNOS
complex, the same conditions were used except that cells were treated
for only 5min and protein lysateswere incubated with anti-PMCA 5F10
monoclonal antibody.
Levels of PMCA4, calcineurin, or eNOS in the immunoprecipitates
were determined bywestern blot using anti-PMCA4 (JA3), anti-calcine-
urin A, or anti-eNOS antibodies.
2.7. Wound healing migration assay
Cell migration of HUVECs and MLECs, treated as indicated, was
assayed using the Cytoselect™ 24-well Wound Healing Assay kit (Cell
Biolabs). Images were captured with a Nikon DSFi1 digital camera
coupled to a Nikon ECLIPSE TS100 microscope at 4× magniﬁcation.
Cell-free area was quantiﬁed with ImageJ software.
2.8. Matrigel tube-formation assay
HUVECs were plated onto Geltrex Reduced Growth-Factor Matrix
(Invitrogen) in Medium 200 with no phenol red and supplemented
with 2% fetal calf serum and 50 ng/ml growth factor (VEGF or bFGF)
in the presence of ATA at the indicated concentration or DMSO as a con-
trol. Tube formation was quantiﬁed after incubation at 37 °C for 16 h.
Images were recorded with a Nikon DSFi1 digital camera coupled to a
Nikon ECLIPSE TS100 microscope at 4× magniﬁcation.
2.9. MTT assay
HUVECs were seeded on 96-well tissue culture plates (without
gelatin pre-coating) at a density of 2.5 × 104 cells/well in supplemented
ECGM (PromoCell). Cell viability was determined byMTT assay [31] the
morning after cell plating (Time = 0) and then after 3 and 6 days of
incubation in supplemented ECGM containing VEGF (25 ng/ml) and
ATA at the indicated concentration or DMSO as control.
2.10. Zebraﬁsh embryo viability
Zebraﬁsh embryos Tg(kdrl:HRAS-mCherry; ﬂk1:EGFP-nls) [7,16]were
manually dechorionated and incubated in increasing concentrations of
ATA or DMSO from 30 hour post fertilisation (hpf) for 24 h. Vascular
morphology was imaged at 54 hpf using a Zeiss Lightsheet Z.1 micro-
scope. Experiments were performed under UK Home Ofﬁce licence
40/3708.
2.11. Murine hindlimb ischaemia
Unilateral hindlimb ischaemia was induced by femoral artery liga-
tion in 12-week-old C57/BL6 mice anaesthetised with 2% isoﬂurane
via inhalation. To induce hindlimb ischaemia maintaining minimal
blood ﬂow to the limb, we ligated a short fragment of the femoral artery
in proximal and distal positions and excised the intervening segment
(this procedure corresponds to the experiments shown in Fig. 7). In a
separate set of experiments, to totally blunt blood ﬂow to the limb, we
performed femoral ligation and excision of the intervening segment
but on this occasion we ligated and excised a longer femoral segment
to induce deep acute ischaemia (this procedure corresponds to the ex-
periments shown in Fig. S5). In all cases, ATA (5 mg/kg) or DMSO(vehicle) was administered intraperitoneally 2 h after the operation,
and then daily as indicated. Blood ﬂow was measured in the sham-op-
erated and ischaemic limbs of anaesthetised animals before surgery,
2 h after the operation, and at the indicated times using a Laser Doppler
Perfusion Imager System (Moor Instruments). Mice were sacriﬁced in
an euthanasia chamber with 70% CO2.
Mouse studies were approved by Animal Care and Ethics committee
at the Centro Nacional de Investigaciones Cardiovasculares and
conformed to directive 2010/63EU and recommendation 2007/562/EC
regarding the protection of animals used for experimental and other
scientiﬁc purposes.
2.12. Nitric oxide determination
To determine intracellular nitric oxide bioavailability HUVECs were
incubated for 3 h in basal ECGM (Promocell) containing 0.5% fetal bo-
vine serum (FBS). After serum starvation, L-arginine was added to a
100 μM ﬁnal concentration and cells were incubated for 15 min. Cells
were then loaded for 30 min with 10 μM of the NO-sensitive ﬂuores-
cence probe DAF-FM (Molecular Probes). Dye-containing medium was
removed and replaced with basal ECGM, 0.5% FBS. Cells were incubated
for 45 min at 37 °C, and then NO synthesis was induced by stimulation
for 5 min with VEGF (25 ng/ml) in the presence of ATA (250 nM) or ve-
hicle (DMSO). After treatment, cells were washed with PBS and ﬁxed in
formalin (Sigma). DAF-FM ﬂuorescence was detected using a ZEISS LSM
880 confocal laser scanning microscope.
2.13. Immunohistochemistry
Tibialis muscle isolated from non-ischaemic (sham-operated) or
ischaemic limbs were ﬁxed in 4% formalin solution, then incubated in
30% saccharose solution, embedded in OCT, frozen in liquid nitrogen,
and ﬁnally cut on a cryotome. VEGF expression was detected by immu-
nohistochemistry using a 1:750 dilution of an anti-VEGF-A rabbit poly-
clonal antibody (1mg/ml, Sigma-Aldrich). A biotinylated anti-rabbit IgG
was used as secondary antibody at a 1:500 dilution. Samples were incu-
bated with a 1:500 dilution of HPR-conjugated streptavidin. Substrate
staining was developed with diaminobenzidine (DAB; Vector
Laboratories).
2.14. Statistical analysis
Results are shown as mean ± S. E. Signiﬁcance of differences
between two groups was analysed by unpaired, two-tailed Student's
t-test. One-way ANOVA with post hoc Tukey's comparison test was
used for comparison among groups. Differences were considered statis-
tically signiﬁcant at P ≤ 0.05.
3. Results
3.1. ATA enhances VEGF-induced calcineurin signalling in endothelial cells
by disrupting the PMCA4/calcineurin interaction
Our previous work demonstrated that PMCA4 negatively modulates
VEGF-induced activation of the calcineurin/NFAT signal transduction
pathway in endothelial cells [4]. The identiﬁcation of the smallmolecule
ATA as a PMCA4 inhibitor [26] prompted us to investigatewhether ATA-
mediated PMCA4 inhibition potentiates VEGF-induced calcineurin/
NFAT signalling.
To explore this possibility, primary HUVECs were infected with the
NFAT-dependent, luciferase-based adenoviral reporter vector Ad-
NFAT-Luc. Inhibition of PMCA4 is reached at low ATA concentrations
in the range of 250 nM [26]. We therefore used this concentration of
ATA in our experiments to achieve inhibition of PMCA4 while avoiding
inhibitory effects on other cellular proteins that have been shown to
require much higher ATA concentrations to be inhibited. Treatment of
Fig. 1. ATA enhances VEGF-induced activation of calcineurin/NFAT signalling in endothelial cells. (A) HUVECs infected with the NFAT-dependent luciferase reporter adenovirus AdNFAT-
Luc (MOI = 50) were treated with VEGF (25 ng/ml) or left untreated (control) in the presence of ATA (250 nM) or vehicle (DMSO). Cells were lysed 6 h post stimulation and luciferase
activity was determined as an index of calcineurin/NFAT pathway activity. Results are expressed as fold-induction over the calcineurin/NFAT activity in DMSO-treated control cells. Data
are shown asmean ± SE, n = 12, obtained from 3 independent experiments. ns= non-signiﬁcant; ***, P ≤ 0.005; ####, P ≤ 0.001; &&&&, P ≤ 0.001 (one-way ANOVA with post hoc Tukey's
comparison test). (B) HUVECs treated as in (A)were lysed 4 h post stimulation, and protein lysateswere analysed bywestern blot to determine the levels of RCAN1.4 and tubulin. RCAN1.4
levelswere normalised to the amount of tubulin in each sample. Data are shown asmean± SE, n= 6, obtained from3 independent experiments.*, P ≤ 0.05 (unpaired two-tailed Student's
t-test) for comparison of cells treated with ATA vs vehicle (DMSO).
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duced calcineurin/NFAT pathway activation by 78.1% (Fig. 1A).
Further analysis on the functional consequences of boosting calcine-
urin signalling with ATA showed that VEGF-induced protein expression
of the NFAT-dependent gene RCAN1.4 was also signiﬁcantly enhanced
(56.8%) by ATA treatment (Fig. 1B).
These data indicate that ATA potentiates the VEGF-induced activa-
tion of the calcineurin/NFAT pathway in endothelial cells, and that this
effect is translated into enhanced expression of NFAT-target genes
such as RCAN1.4.
PMCA4 is thought to downregulate calcineurin/NFATpathway activ-
ity through a molecular interaction that sequesters calcineurin into
low calcium micro-domains created by the pump's calcium extrusion
activity [18]. Supporting this idea, disruption of the PMCA4/calcineurin
interaction notably potentiates calcineurin/NFAT signalling [4]. We
therefore next examined whether the ATA-enhanced calcineurinFig. 2. ATA releases calcineurin from interaction with PMCA4 in the endothelial cell plasma m
plasma membrane protein fraction of serum-starved HUVECs treated for 4 h with VEGF (
membrane-associated calcineurin normalised to the amount of cadherin present in each sam
lysates prepared with Laemmli buffer from HUVECs treated as in (A). The histogram shows le
Immunoprecipitation/western blot analysis of calcineurin (CnA) and PMCA4 in protein com
HUVECs treated as in (A). The histogram shows levels of co-precipitated PMCA4 normalised to
independent experiments. Histograms show data as mean ± SE, obtained from 3 independe
plasma membrane levels of calcineurin in VEGF-stimulated cells treated with ATA vs veh
precipitated PMCA4 in VEGF-stimulated HUVECs treated with ATA vs vehicle (DMSO). ns = nosignalling is associated with changes in the interaction between the
two proteins. Membrane-associated proteins were isolated from
HUVECs treated with VEGF in the presence or absence of ATA and
analysed for the content of PMCA4 and calcineurin. ATA treatment sig-
niﬁcantly reduced the level of membrane-associated calcineurin,
whereas the levels of PMCA4 remain unaffected (Fig. 2A), suggesting
that treatment of HUVECs with ATA releases calcineurin from its inter-
action with PMCA4 in the plasma membrane. Analysis of whole-cell
extracts revealed similar levels of calcineurin in control (DMSO) and
ATA-treated cells, excluding an effect of ATA on calcineurin expression
(Fig. 2B). Total levels of PMCA4 were similarly unaffected in the same
samples (Fig. 2B).
To conﬁrm that the decrease in membrane-associated calcineurin
was due to disruption of the PMCA4/calcineurin interaction, we per-
formed immunoprecipitation experiments. Protein extracts from
HUVECs stimulated with VEGF in the presence or absence of 250 nMembrane. (A) Western blot analysis of calcineurin A (CnA), PMCA4, and cadherin in the
25 ng/ml) plus ATA (250 nM) or vehicle (DMSO). The histogram shows the levels of
ple. (B) Western blot analysis of calcineurin A (CnA), PMCA4 and tubulin (Tub) in total
vels of total calcineurin normalised to the amount of tubulin present in each sample. (C)
plexes immunoprecipitated with anti-calcineurin antibody from total protein lysates of
the amount of calcineurin precipitated in each assay. (A–C) Blots are representative of 3
nt experiments. **, P ≤ 0.01 (unpaired two-tailed Student's t-test) for comparison of the
icle (DMSO). *, P ≤ 0.05 (unpaired two-tailed Student's t-test) for comparison of co-
n-signiﬁcant.
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blot analysis of the immunoprecipitated proteins revealed that ATA
treatment markedly reduced the amount of PMCA4 co-precipitated
with calcineurin, suggesting dissociation of the PMCA4/calcineurin
complex (Fig. 2C). No signiﬁcant differences were found in the
amount of immunoprecipitated calcineurin in control and ATA-treated
cells (Fig. 2C), excluding an effect of ATA on the afﬁnity of the
immunoprecipitating antibody for calcineurin.
Together, these data suggest that treatment of endothelial cells with
ATA liberates calcineurin from its interaction with PMCA4, thereby po-
tentiating VEGF-mediated activation of calcineurin/NFAT signalling
and the subsequent expression of NFAT-target genes such as RCAN1.4.Fig. 3.ATA increases endothelial cellmotility by inhibiting PMCA4 and disrupting the PMCA4/ca
with HUVECs (A), PMCA4+/+ or PMCA4−/−MLECs (B), and AdLacZ- or AdID4-infected HUVECs
ATA (250 nM) or vehicle (DMSO). (A)Data are shown asmean±SE, n=9, obtained from3 ind
of cells treatedwith ATA vs vehicle (DMSO). (B) Data are shown asmean± SE, n= 6, obtained
one-wayANOVAwith post hoc Tukey's comparison test. ***, P ≤ 0.005 for comparison ofmigratio
of motility inwild-type (+/+) vs PMCA4 knockout (−/−) MLECs. ns= non-signiﬁcant. (C) Da
were analysed for statistical signiﬁcance by one-way ANOVA with post hoc Tukey's compariso
vehicle (DMSO). ###, P ≤ 0.005 for comparison of migration in cells infected with AdLacZ vs A
for 24 h. The migrated area was calculated by subtracting the value of the non-migrated area
time zero. Scale bars, 1000 μm.3.2. ATA increases VEGF-mediated endothelial cell motility and blood vessel
formation
PMCA4-mediated inhibition of calcineurin/NFAT signalling nega-
tively regulates endothelial cell migration and tubular morphogenesis
[4]. The enhanced calcineurin/NFAT signalling induced by ATA in
VEGF-stimulated HUVECs (Fig. 1) suggested that ATA might reverse
the negative effect of PMCA4 on these angiogenic processes.
In wound-healing migration assays, exposure of VEGF-stimulated
HUVECs to ATA increased cell migration by 58.4% (Fig. 3A).
To determine whether the ATA-dependent increase in endothelial
cell motility involves PMCA4 inhibition, and is not the consequence oflcineurin interaction. Representative images ofwound-healingmigration assays performed
(C) incubated in culture medium supplemented with VEGF (25 ng/ml) in the presence of
ependent experiments. ***, P ≤ 0.005 (unpaired two-tailed, Student's t-test) for comparison
from 3 independent experiments. Differences were analysed for statistical signiﬁcance by
n by PMCA4+/+MLECs treatedwith ATA vs vehicle (DMSO). ####, P ≤ 0.001 for comparison
ta are shown as mean± SE, n= 3, obtained from 3 independent experiments. Differences
n test. *, P ≤ 0.05 for comparison of motility in AdLacZ-infected cells treated with ATA vs
dID4. ns = non-signiﬁcant. Images in (A-C) were taken at time zero and after incubation
from the wound area at time zero, and expressing this as a percentage of the total area at
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endothelial cells (MLECs) isolated from PMCA4−/− knockout mice or
their wildtype littermates. Consistent with our published observations
[4], PMCA4-deﬁcient cells migrated over longer distances than their
wildtype counterparts (Fig. 3B). However, whereas ATA increased
wildtype MLEC migration by 64.7%, it had no effect on the migration
of PMCA4-deﬁcient MLECs (Fig. 3B).
To investigate whether the ATA-mediated enhanced endothelial cell
motility is linked to disruption of the PMCA4/calcineurin interaction,we
performed cell migration assays using HUVECs infectedwith Ad-ID4, an
adenoviral vector encoding a PMCA4 region that successfully disrupts
association between the two proteins [4]. As a control, HUVECswere in-
fected with an adenovirus encoding β-Galactosidase (Ad-LacZ). ATAFig. 4. ATA enhances endothelial cell tubular morphogenesis induced by VEGF but not by bFGF.
FBS, were treated when indicated with VEGF (50 ng/ml) (A) or bFGF (50 ng/ml) (C) in the
experiments quantiﬁed in the histogram. Data are shown as mean ± SE, n = 6 in (A) and n =
= non-signiﬁcant; ***, P ≤ 0.005; #, P ≤ 0.05; ####, P ≤ 0.001; &, P ≤ 0.05; &&&&, P ≤ 0.001 (unpa
P ≤ 0.005 (one-way ANOVA with post hoc Tukey's comparison test). (B) Tubular morphogen
targeting control siRNA (si-NT). Transfected cells were plated on Growth-Factor Reduced Mat
presence of ATA (250 nM) or vehicle (DMSO). Images show representative ﬁelds from experim
independent experiments. ns = non-signiﬁcant; ***, P ≤ 0.005 (one-way ANOVA with post hocincreased themigration of Ad-LacZ-infected cells (Fig. 3C). As we previ-
ously reported [4], disruption of the PMCA4/calcineurin interaction in
Ad-ID4-infected HUVECs increased cell migration (Fig. 3C), however
ATA-treatment did not further increase migration (Fig. 3C). Ad-ID4-in-
fected cells treated with DMSO or ATA expressed equal amounts of
ID4, excluding an effect of ATA on adenovirus infection efﬁciency
(Fig. S1). These data not only conﬁrm the implication of PMCA4 in
ATA-enhanced endothelial cellmigration, but also reveal that disruption
of the interaction between PMCA4 and calcineurin is a key molecular
mediator of this process.
PMCA4 and the calcineurin/NFAT pathway both have well-
established roles in the regulation of blood vessel formation [2,4,14].
We therefore next investigated the effect of ATA on endothelial cellHUVECs plated on Growth-Factor ReducedMatrix (Geltrex) inMedium 200 containing 2%
presence of ATA (250 nM) or vehicle (DMSO). Images show representative ﬁelds from
4 in (C), and were obtained from 3 and 2 independent experiments, respectively. (A) ns
ired two-tailed Student's t-test). (C) ns = non-signiﬁcant; **, P ≤ 0.01; ***, P ≤ 0.005; ###,
esis analysis in HUVECs transfected with a PMCA4-speciﬁc siRNA (si-PMCA4) or a non-
rix (Geltrex) in Medium 200 containing 2% FBS, and treated with VEGF (50 ng/ml) in the
ents quantiﬁed in the histogram. Data are shown as mean ± SE, n = 9 obtained from 3
Tukey's comparison test). (A–C) Scale bars, 1000 μm.
Fig. 5.ATA treatment potentiates the PMCA4/eNOS interaction and attenuates nitric oxide
synthesis in endothelial cells stimulated with VEGF. (A) Serum-starved HUVECs were
treated with VEGF (25 ng/ml) and ATA (250 nM) or vehicle (DMSO) for 5 min. Protein
lysates were immunoprecipitated with the anti-PMCA 5F10 monoclonal antibody, and
levels of PMCA4 and eNOS in the immunoprecipitated proteins analysed by western
blot. Histogram shows levels of co-precipitated eNOS normalised to the amount of
PMCA4 precipitated in each assay. Data are shown as mean ± SE obtained from 3
independent experiments. ** indicates statistically signiﬁcant differences (P ≤ 0.01,
according to unpaired, two-tailed Student's t-test) in the levels of eNOS co-precipitated
in samples treated with ATA vs DMSO. Western blot images are representative of 3
independent immunoprecipitation experiments. (B) HUVECs were treated as indicated
in (A). Intracellular levels of nitric oxide were determined by staining cells with the NO-
sensitive dye DAF-FM. Images showing microscopy ﬁelds of DAF-FM staining in cells are
representative of 2 independent experiments. Scale bars, 20 μm.
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increased the ability of HUVECs to form capillary-like structures in
Matrigel assays (Fig. 4A). VEGF-induced tube formation was further en-
hanced by co-treatment with ATA (38.9% increase with respect to con-
trol cells) (Fig. 4A). To substantiate the involvement of PMCA4 on the
boost in VEGF-induced endothelial cell tubular morphogenesis exerted
by ATA, we suppressed PMCA4 expression in endothelial cells using
siRNA-mediated technology (Fig. S2). ATA signiﬁcantly enhanced endo-
thelial cell tubular morphogenesis in VEGF-stimulated cells transfected
with a control non-target siRNA (si-NT) (Fig. 4B). As expected, suppres-
sion of PMCA4 expression in cells transfected with siRNA targeting
PMCA4 (si-PMCA4) increased the ability of the cells to form capillary-
like structures in response to VEGF (Fig. 4B), however ATA failed to fur-
ther increase tubular morphogenesis in these cells (Fig. 4B). This result
demonstrates the involvement of PMCA4 in the enhancement of blood
vessel formation induced by ATA in endothelial cells stimulated with
VEGF.
Interestingly, ATA did not boost tubular morphogenesis in HUVECs
stimulated with basic ﬁbroblast growth factor (bFGF), a pro-angiogenic
factor that does not activate calcineurin signalling [14] (Fig. 4C).
These observations suggest that inhibition of PMCA4 with ATA
markedly enhances VEGF-induced endothelial cell motility and tubular
morphogenesis in a calcineurin/NFAT-dependent manner.
Altogether, these results highlight the clinical potential of PMCA4 in-
hibition and/or disruption of the PMCA4/calcineurin interaction to de-
sign novel therapeutic approaches that improve VEGF-induced
angiogenesis in patients with cardiovascular ischaemic disease.
3.3. ATA promotes PMCA4/eNOS interaction and attenuates nitric oxide
synthesis in endothelial cells
Our results in this work establish a major role for the calcineurin/
NFAT signalling pathway in the enhancement of VEGF-induced angio-
genesis upon inhibition of PMCA4 with ATA; however, they do not ex-
clude the potential participation of other signalling pathways. In
addition to calcineurin, we recently showed that PMCA4 also
downregulates the activity of eNOS and the subsequent production of
nitric oxide (NO) in endothelial cells [19]. The pro-angiogenic proper-
ties of NO are well established [24,45], and VEGF activates eNOS-medi-
ated NO production in endothelial cells [25]. Thus we decided to
investigate the effect of ATA on the PMCA4/eNOS interaction, and in
the induction of NO synthesis mediated by VEGF in endothelial cells.
For this purpose, protein lysates isolated from HUVECs stimulated
with VEGF in the presence or absence of 250 nM ATA were
immunoprecipitated with the anti-PMCA antibody 5F10. Western blot
analysis of immunoprecipitated proteins showed that ATA strongly in-
creased the amount of eNOS co-precipitated with PMCA4 (Fig. 5A). No
signiﬁcant differences were observed in the amount of PMCA4 precipi-
tated in control or ATA-treated cells (Fig. 5A) ruling out an effect of ATA
on the afﬁnity of the immunoprecipitating antibody for PMCA4. This re-
sult indicates that ATA promotes the association between PMCA4 and
eNOS. Accordingly, functional experiments in HUVECs showed that
ATA (250 nM) signiﬁcantly attenuate NO synthesis in VEGF-stimulated
cells (Fig. 5B), excludingNO as an effector of the enhancement in angio-
genesis mediated by ATA.
3.4. Low ATA levels are not toxic to endothelial cells
Our observations suggest that inhibition of PMCA4 with ATA has
therapeutic potential for the promotion of blood vessel formation in sit-
uations characterized by insufﬁcient angiogenesis. To evaluate this pos-
sibility we ﬁrst monitored for any effect of ATA on endothelial cell
viability. Exposure of HUVECs to 250 nMATA did not affect proliferation
or cell viability (Fig. 6A), and also had no effect on the VEGF-induced
phosphorylation (activation) status of Erk1/2 (Fig. 6B), indicating thatlow ATA concentrations do not modify the activity of this proliferative
signal transduction pathway.
In contrast, long-term exposure of HUVECs to a higher concentration
(20 μM) reduced cell viability (Fig. S3A) and abolished the ability of
VEGF-stimulated HUVECs to form capillary-like structures in matrigel
assays (Fig. S3B). To investigate the reasons underlying the toxic effects
of high concentrations of ATA on endothelial cells, we ﬁrst determined
whether micromolar concentrations of ATA might induce any changes
in the pH of the culture medium. Analysis of cultures of HUVECs incu-
bated in medium containing vehicle (DMSO), or ATA at low (0.25 μM)
or high (20 μM) concentration for different periods showed no differ-
ences in the pH of themedium (Fig. S3C). Another possibility to explain
the harmful effect of 20 μM ATA on the viability of endothelial cells
could be that high ATA concentrations in the culture mediummight re-
sult in deleterious osmotic stress on the cells. To test this possibility we
checked the activation of ATF-2, a transcription factor well-known to
Fig. 6. Low concentration ATA is not toxic to endothelial cells. (A) MTT assay cell viability in HUVECs after overnight incubation (t = 0) and incubation for 3 and 6 days in medium
supplemented with VEGF (25 ng/ml) in the presence of ATA (250 nM) or vehicle (DMSO). Data are shown as mean ± SE, n = 3, obtained from 3 independent experiments. (B)
Western blot analysis of the phosphorylation (activation) status of Erk1-2 proteins in HUVECs stimulated as indicated with VEGF for 5 min in the presence of ATA (250 nM) or vehicle
(DMSO). Data are shown as mean ± SE, n = 5, obtained from 3 independent experiments. Erk1-2 phosphorylation levels were normalised to the amount of total Erk1-2 present in
each sample. Data are expressed as the fold-induction in Erk1-2 phosphorylation relative to the value in unstimulated cells. ns = non-signiﬁcant.
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medium containing low or high concentrations of ATA. No changes in
the phosphorylation (activation) status of ATF-2 were detected in cells
grown in medium containing 20 μM ATA compared to cells grown in
0.25 μM ATA or vehicle (DMSO) (Fig. S3D). Osmotic stress induced by
high concentration of NaCl in the medium resulted in ATF-2 phosphor-
ylation conﬁrming the suitably of the assay (Fig. S3D).
To analyse potential toxic effects of ATA in a more physiological set-
ting, we treated zebraﬁsh embryos with increasing ATA concentrations.
Consistent with the in vitro data, low ATA concentrations (50–100 μM)
caused no signiﬁcant damage to embryos, which developed a normal
vascular anatomy (Fig. S4). In contrast, exposure to ATA concentrations
above 100 μMwas associated with embryo death (Fig. S4).
Although our results demonstrate proof-of-concept for pharmaco-
logical targeting of PMCA4 in therapeutic approaches, reﬁned versions
of ATA with high speciﬁcity for PMCA4 will be required to design efﬁ-
cient and safe clinical interventions.
3.5. ATA enhances post-ischaemic hindlimb perfusion in vivo
To evaluate in vivo the therapeutic potential of PMCA4 inhibition to
promote reperfusion of ischaemic tissues, we used the mouse hindlimb
ischaemia model. We have used two surgical approaches to induce dif-
ferent levels of ischaemia in the lower limb of mice [8,21]. In a ﬁrst ap-
proach, limb ischaemia was induced by proximal and distal ligation of a
short fragment of the femoral artery with excision of the interveningFig. 7. Administration of ATA at low concentration boosts post-ischaemic hind limb perfusion
in sham-operated non-ischaemic legs (S) and femoral-ligated ischaemic legs (I) of mice recei
as mean ± SE, n = 7, obtained from 2 independent experiments. **, P ≤ 0.01 (unpaired two-t
vs vehicle. ns = non-signiﬁcant.segment. This procedure induces limb ischaemia by signiﬁcantly reduc-
ing theﬂowof blood to the limbbut stillmaintains a lowdegree of blood
ﬂow to the muscle. Initially we chose this model to maintain a low de-
gree of blood ﬂow that could mediate the delivery of ATA to the ischae-
mic organ. To evaluate the effect of ATA on this setting, vehicle (DMSO)
or ATA was administered intraperitoneally 2 h after surgery and daily
for 3 more days. Given the harmful effects of high ATA concentrations
(Fig. S3 and S4) we selected a dose of 5 mg/kg/day, which is not associ-
ated with damage in mice [27]. Laser Doppler imaging analysis of blood
ﬂow performed 4 days after surgery revealed a signiﬁcant increase in
the reperfusion of post-ischaemic limbs treatedwith ATA (Fig. 7). To ex-
plore whether ATA would be able to exert the same effect in a model of
deep acute ischaemia, in a separate set of experiments we performed
femoral ligation and excision of the intervening segment but on this oc-
casionwe ligated and excised a longer femoral segment. This procedure
totally blunted blood ﬂow to the lower limb (Fig. S5A). As expected, loss
of blood ﬂow resulted in a strong upregulation of VEGF expression in
the ischaemic limb (Fig. S6). Blood ﬂow to the ischaemic limb was pro-
gressively recovered along time (Fig. S5A). In concurrence with our ini-
tial data, administration of ATA to these animals also enhanced
signiﬁcant reperfusion of the ischaemic limb (Fig. S5A–B) although, in
this case, administration of ATA for 7–10 days was required to detect
the enhancement of blood ﬂow mediated by the drug. It is likely that
in this model, a longer period of ATA administration is required because
ATA delivery to the ischaemic area is compromised during the ﬁrst days
post-surgery due to the absence of blood ﬂow.in mice. Representative laser Doppler images showing blood ﬂow at 4 days after surgery
ving ATA (5 mg/kg/day) or vehicle (DMSO) by intraperitoneal injection. Data are shown
ailed Student's t-test) for comparison of ischaemic-leg blood ﬂow in mice receiving ATA
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apeutic potential of pharmacological targeting of PMCA4 to promote tis-
sue reperfusion in patients with ischaemic cardiovascular disease.
4. Discussion
In this study, we demonstrate that inhibition of the plasma mem-
brane calcium ATPase 4 (PMCA4) with low concentrations of the
small polyaromatic compound aurintricarboxylic acid (ATA) signiﬁ-
cantly enhances VEGF-induced angiogenic processes. Our results show
proof-of-concept for targeting PMCA4 therapeutically to improve
VEGF-based pro-angiogenic interventions in patients with ischaemic
cardiovascular disease. In this work we have used ATA to inhibit the
function of PMCA4. The feasibility of ATA as a clinical treatment has
yet to be tested, but pre-clinical studies in animal models have revealed
potential clinical applications in the treatment of cardiac hypertrophy
[27], experimental autoimmune encephalomyelitis [43], sepsis [22],
and myocardial ischaemia-reperfusion injury [44].
Our results show that high levels of ATA strongly reduce endothelial
cell viability and abolish tube formation. Consistent with our results,
Lipo et al. [23] reported that increasing ATA concentrations diminish
the ability of endothelial cells to form tubular-like structures inmatrigel
assays. Furthermore, in the same study, the authors report that intravit-
real injection of 1.5 μgATA in 2 μl 10%DMSO (corresponding to 1.78mM
ATA) into mice strongly attenuates laser-induced choroidal neovascu-
larization. It is highly likely that the reduced ocular vascularization ob-
served by Lipo et al. [23] results from the toxicity associated with high
ATA concentrations, an interpretation supported by our experiments
in zebraﬁsh embryos (Fig. S4) and those reported by Smee et al. [36]
in mice. Furthermore, 5–20 μM ATA has been shown to reduce the
growth rate of ﬁbroblasts [5] and smooth muscle cells [6]. In this work
we have not identiﬁed the mechanisms underlying the harmful effect
on endothelial cell viability exerted by high levels of ATA but, at these
concentrations, ATAhas been reported to non-speciﬁcally inhibit the ac-
tion of nucleases [13], calpain [32] and several chemokine receptors
[43], suggesting possible explanations for the toxicity of high-concen-
tration ATA. The deleterious effects exerted by ATA at high concentra-
tions indicate that reﬁned, highly selective versions of this molecule
will be required for efﬁcient therapeutic interventions to treat patients
with chronic ischaemic disease without associated harmful side-effects.
Mechanistically, ATA enhances VEGF-induced activation of the cal-
cineurin/NFAT pathway in endothelial cells, in turn boosting calcine-
urin-dependent angiogenic processes such as endothelial cell
migration and tubular morphogenesis. Our data indicate that ATA in-
creases calcineurin signalling by disrupting its interaction with calcine-
urin at the plasma membrane. At present, we do not know the
molecular process by which ATA disrupts the PMCA4/calcineurin com-
plex. A possible explanation is masking by ATA of the calcineurin-
interacting region in PMCA4 (amino acids 428 to 651 in human
PMCA4b) [9]. Supporting this possibility, ATA inhibits hepatitis C
helicase by a similar mechanism, binding to a deﬁned region in the en-
zyme and thereby blocking interaction with nucleic acids [35]. Howev-
er, a different picture emerges from analysis of the effect of ATA on
PMCA4 binding to endothelial nitric oxide synthase (eNOS), which in-
teracts with the same PMCA4 domain as calcineurin [19]. Rather than
decreasing the interaction, ATA promotes association between PMCA4
and eNOS (Fig. 5A). The opposite effects of ATA on PMCA4 binding to
calcineurin or eNOS suggests that ATA is unlikely to be an allosteric
competitor with partner proteins for binding to the 428–651 PMCA4
domain. It will be interesting in future research to fully deﬁne the mo-
lecular events implicated in ATA-mediated disruption of PMCA4/cal-
cineurin interaction and the differential effect of ATA on PMCA4
binding to calcineurin or eNOS.
The results presented here establish a key role for the calcineurin/
NFAT signalling pathway in the enhancement of VEGF-induced angio-
genesis upon inhibition of PMCA4 with low ATA concentrations. Wehave previously reported that PMCA4 also downregulates eNOS activity
and NO production in endothelial cells [19]. Here, we show that ATA at-
tenuates VEGF-induced nitric oxide production in endothelial cells, sug-
gesting that NO signalling is not implicated in the enhancement of
angiogenesis mediated by ATA; however, our results do not exclude
the potential participation of other signalling pathways. Further investi-
gations into the molecular mechanisms underlying ATA-mediated en-
hancement of VEGF signalling promise to reveal novel molecular
targets for improving pro-angiogenic therapy.
Our in vivo experiments in animal models of experimentally in-
duced hindlimb ischaemia show that ATA enhances reperfusion of
post-ischaemic limbs. Given that our experiments using HUVECs in
culture have shown that ATA markedly enhances VEGF-induced
angiogenesis in vitro, it is likely that the increase in reperfusion
of post-ischaemic limbs induced by ATA involves increased
revascularisation of the muscle, although a full characterization of
the effect of ATA on angiogenesis in vivo will require further
investigations.
The present study indicates that targeting PMCA4 could improve
VEGF-based pro-angiogenic interventions, highlighting the clinical po-
tential of using PMCA4 inhibitors for the treatment of ischaemic cardio-
vascular disease. Interestingly, in addition to theATA-mediated increase
in reperfusion of ischaemic limbs, a trend to increase blood ﬂow in non-
ischaemic (sham-operated) muscle was also observed in the animals
treated with ATA (Fig. 7 and S5) although these differences did not
reach statistical signiﬁcance (P = 0.0558). Our ﬁndings in cultured
HUVECs have shown that ATA enhances blood vessel formation in the
presence of VEGF but does not have any effect when it is added to
serum-starved cells (Fig. 4). We speculate that the increased blood
ﬂow in non-ischaemic limbs of animals treated with ATA might be the
result of ATA acting in conjunction with low physiological levels of
VEGF normally present in themuscle (Fig. S6).We think this is extreme-
ly interesting from a therapeutic point of view, as one of themain obsta-
cles for success of current VEGF-based therapeutic strategies is the
difﬁculty to achieve high ectopic expression of VEGF in the ischaemic
organ [42]. In fact, although it is thought that VEGF-based gene therapy
is the best way forward in future therapeutic approaches, adenoviral
vectors only transduce a small percentage of the target cells in humans
[41]. Thus, selective PMCA4 inhibitors might be useful co-adjuvants in
VEGF-based gene therapy strategies to enhance reperfusion of ischae-
mic tissues even in situations where expression of ectopic VEGF is not
very high. Our in vivo data in this work do not allow evaluating the efﬁ-
ciency of single versus combined ATA/VEGF therapies. Further studies
are required to analyse the pharmacokinetics of single and combined
ATA/VEGF therapies in preclinical animalmodels of cardiovascular isch-
aemic disease.Funding
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